Given the relevance of the interaction of CD6 and its ligands in the pathophysiology of autoimmune diseases and cancer, as well as the growing evidence of the role of modulation of these associations as revolutionary immunotherapies (3, 19, 20), this work aimed to evaluate whether CD6 modulation by the only clinically approved anti-CD6 antibody itolizumab improves the immune response against tumor cells. The gene discussed is CD6; the disease is autoimmune disease.